Fundraising FoxBain Capital Life Sciences — 2026 Investments
7 investments dated 2026 · listed companies and verified rows first · show all
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham VenturesREDMILE+9 more
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Co-investorsCatalio Capital Management, LPProto AxiomSanofi VenturesSV Health InvestorsTenmileAbingworth+2 more
Beeline provides vendor management system (VMS) software for managing contingent and external workforces, including staffing suppliers and shift-based labor.
Future of WorkHR TechSaaS
Co-investorsAcadian Ventures Management, Llc
Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.
AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US
Aaron Hurst(Founder)in
Co-investorsEmpire AngelsGaingelsSand Hill AngelsVoyager CapitalAlly Bridge GroupAmed Ventures+6 more
__Twitter.png)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Bridge TO LifeCaldera Therapeutics, Inc.OMass Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.